What happens if MAT stops?

When medication-assisted treatment stops, individuals may experience changes in withdrawal stability, cravings, opioid tolerance, relapse vulnerability, and nervous system functioning depending on the medication involved and the duration of prior treatment. Methadone and buprenorphine-based medications can produce withdrawal symptoms because they activate opioid receptors and may lead to physical dependence over time. Naltrexone-based treatments involve different effects because the medication blocks opioid receptors rather than activating them.

Discontinuation of methadone or buprenorphine may lead to withdrawal symptoms such as anxiety, insomnia, sweating, gastrointestinal distress, muscle aches, irritability, agitation, and increased craving intensity. The severity and duration of symptoms vary depending on dosage, treatment length, metabolism, opioid history, and nervous system adaptation. Long-acting medications may produce more prolonged withdrawal timelines compared to short-acting opioids.

Stopping MAT may also increase relapse and overdose risk because opioid tolerance often decreases during treatment. If opioid use resumes after tolerance reduction, previously tolerated doses may become significantly more dangerous. This risk is especially important in fentanyl-related opioid exposure because of fentanyl’s potency and overdose potential.

Psychiatric symptoms, trauma exposure, chronic stress, sleep disruption, environmental instability, and co-occurring mental health disorders may further affect recovery stability after MAT discontinuation. Anxiety disorders, depression, PTSD, and emotional dysregulation commonly influence relapse vulnerability and post-treatment adjustment. Recovery outcomes are therefore shaped by both neurological and environmental factors simultaneously.

The effects of stopping MAT are generally evaluated within the broader context of chronic addiction management and relapse prevention rather than medication discontinuation alone. Research has consistently shown increased relapse and overdose vulnerability following premature treatment cessation in some populations. Ongoing clinical assessment commonly considers overdose risk, recovery stability, psychiatric symptoms, and environmental conditions when evaluating MAT discontinuation.